EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization

Grammati Sarri, Bengt Liljas iD, Keith R Abrams, Stephen J Duffield, Murtuza Bharmal iD

Journal of Market Access & Health Policy · 08.04.2026 · 14 (2) · 20

DOI: 10.3390/jmahp14020020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Market Access & Health Policy, online erschienen am 08.04.2026. Verfasst von Grammati Sarri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Evidence, Value and Access, Cytel Inc., London WC1H 9BB, UK. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methodological guidelines for real-world evidence (RWE) in European Union (EU) joint clinical assessments (JCA) are lacking. This manuscript explores RWE potential in EU health technology assessment (HTA) and offers recommendations for generating high-quality RWE. An environmental scan of peer-reviewed and gray literature was conducted to review RWE frameworks and documents in EU regulatory and HTA decision-making. Extraction elements were standardized across key RWE themes: data quality, methodological rigor, stakeholder engagement, and applications. In JCA, RWE has multiple uses, including informing PICO simulation exercises, understanding disease landscape, identifying prognostic factors and effect modifiers, and directly or indirectly informing comparative clinical assessments. Methodological guidance from the HTA Coordination Group is limited to cases in which evidence from non-randomized studies is used as direct inputs in comparative assessments. Individual HTA bodies provide more detailed guidance, missing an opportunity to leverage RWE within JCAs that can offer insight for local Member State submissions. Generating high-quality RWE that is credible, actionable, and acceptable for JCA submissions and local HTA bodies requires careful attention to methodological considerations and early planning. Broader RWE integration that reflects patient journeys is needed. Expanding the HTA Coordination Group guidance can unlock RWE’s full potential in supporting EU JCA submissions.

Schlagwörter

Stichwörter der Autor:innen

European Unionguidancehealth technology assessmentjoint clinical assessmentsreal-world datareal-world evidence

Autor:innen und Institutionen

  • Evidence, Value and Access, Cytel Inc., London WC1H 9BB, UK.
  • Health Economics & Payer Evidence, OMAP, AstraZeneca, Gaithersburg, MD 20878, USA.
  • Department of Statistics & Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
  • Real World Evidence Methods, NICE, London E20 1JQ, UK.
  • Oncology Outcomes Research, AstraZeneca, Boston, MA 02210, USA.

ORCID-Profile: Bengt Liljas, Murtuza Bharmal

Förderung

  • AstraZeneca

Zitieren

APA

Sarri, G., Liljas, B., Abrams, K. R., Duffield, S. J., & Bharmal, M. (2026). Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization. Journal of Market Access & Health Policy, 14(2), 20. https://doi.org/10.3390/jmahp14020020

Vancouver

Sarri G, Liljas B, Abrams KR, Duffield SJ, Bharmal M. Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization. Journal of Market Access & Health Policy. 2026;14(2):20. doi:10.3390/jmahp14020020

BibTeX
@article{Sarri2026,
  author = {Sarri, Grammati and Liljas, Bengt and Abrams, Keith R and Duffield, Stephen J and Bharmal, Murtuza},
  title = {Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization},
  journal = {Journal of Market Access & Health Policy},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {20},
  doi = {10.3390/jmahp14020020}
}
Kostenlos starten →